Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amivantamab (Primary) ; Carboplatin (Primary) ; Lazertinib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PALOMA-2
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 23 Feb 2026 According to Johnson & Johnson media release, the company announced that the European Commission (EC) has approved an extension of the RYBREVANT marketing authorisation to include additional subcutaneous (SC) dosing regimens. The approval is supported by results from the Phase 2 PALOMA-2 and Phase 1 PALOMA studies.
  • 17 Feb 2026 According to Johnson & Johnson media release, company announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj).
  • 15 Oct 2025 According to Johnson & Johnson media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) 2025 Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top